2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).
Warmus, J.S., Flamme, C., Zhang, L.Y., Barrett, S., Bridges, A., Chen, H., Gowan, R., Kaufman, M., Sebolt-Leopold, J., Leopold, W., Merriman, R., Ohren, J., Pavlovsky, A., Przybranowski, S., Tecle, H., Valik, H., Whitehead, C., Zhang, E.(2008) Bioorg Med Chem Lett 18: 6171-6174
- PubMed: 18951019 
- DOI: https://doi.org/10.1016/j.bmcl.2008.10.015
- Primary Citation of Related Structures:  
3EQB - PubMed Abstract: 
This paper reports a second generation MEK inhibitor. The previously reported potent and efficacious MEK inhibitor, PD-184352 (CI-1040), contains an integral hydroxamate moiety. This compound suffered from less than ideal solubility and metabolic stability. An oxadiazole moiety behaves as a bioisostere for the hydroxamate group, leading to a more metabolically stable and efficacious MEK inhibitor.
Organizational Affiliation: 
Department of Chemistry, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. Joseph.Warmus@Pfizer.com